Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CANO HEALTH Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
UNITEDHEALTH | 308,30 | +1,00 % | UnitedHealth auf Erholungskurs: Hatte Buffett den richtigen Riecher? | In den zurückliegenden Handelswochen hat sich die Aktie des größten US-Krankenversicherers von den Tiefständen lösen können. Der Einstieg von Investmentlegende Warren Buffett mit seiner Beteiligungsgesellschaft... ► Artikel lesen | |
INTUITIVE SURGICAL | 375,00 | +1,36 % | ISRG Shares Rise as FDA Clears AI Integration for Ion Platform | ||
THERMO FISHER | 457,95 | +1,32 % | What to Expect From Thermo Fisher's Q3 2025 Earnings Report | ||
ROKU | 82,01 | +3,30 % | The Roku Streaming Stick Plus was one of my Prime Day favorites - and it's still on sale | ||
ATOSSA THERAPEUTICS | 0,907 | -7,07 % | Atossa Therapeutics Inc: Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities | Changes are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans
SEATTLE, Oct. 6, 2025 /PRNewswire/... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
CENTENE | 31,170 | +1,23 % | Centene stock price target maintained at $38 by Cantor Fitzgerald | ||
QUIDELORTHO | 23,000 | +0,88 % | QuidelOrtho Corporation: QuidelOrtho Completes Debt Refinancing | SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic... ► Artikel lesen | |
VERU | 3,910 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
NANO-X IMAGING | 3,905 | 0,00 % | Nano-X Imaging LTD.: Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC | Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH... ► Artikel lesen | |
FULGENT GENETICS | 19,000 | -2,06 % | Fulgent Genetics: A Risky Bet or a Hidden Gem? | ||
LANTHEUS | 47,140 | +2,26 % | What 6 Analyst Ratings Have To Say About Lantheus Holdings | ||
PERSPECTIVE THERAPEUTICS | 4,300 | +2,38 % | BTIG initiates coverage on Perspective Therapeutics stock with Buy rating | ||
AMN HEALTHCARE SERVICES | 16,000 | +1,91 % | AMN Healthcare schließt Anleiheemission über 400 Mio. USD ab und passt Kreditfazilität an |